美国食品和药物管理局批准阿斯迪斯制药公司的Yorvipath激素治疗治疗美国成人甲状腺功能低下患者. FDA approves Ascendis Pharma's Yorvipath hormone disorder therapy for US adult hypoparathyroidism patients.

亚盛迪斯制药公司的Yorvipath,一种激素治疗,已被FDA批准用于患有甲状腺功能低下症的成年患者,这是一种罕见的内分泌疾病,在美国约有70,000到90,000人受到影响. Ascendis Pharma's Yorvipath, a hormone disorder therapy, has been approved by the FDA for adult patients with hypoparathyroidism, a rare endocrine disease affecting approximately 70,000 to 90,000 people in the US. Yorvipath将是2022年底Takeda停止注射Natpara后美国唯一核准的治疗。 Yorvipath will be the only approved treatment in the US after Takeda discontinues its injection, Natpara, at the end of 2022. Ascandis预计到2025年第1季度将有初步供应。 Ascendis anticipates initial supply to be available in Q1 2025.